Home › Companies › ACLARIS THERAPEUTICS INC. › 2023-2024
Compiled from SEC Form N-PX filings and ACLARIS THERAPEUTICS INC.’s Form 8-K, filed 2024-06-07 (Item 5.07 on EDGAR). Page generated 04 October 2026.
Proxy season: 2023-2024 2025-2026
Explore ACLARIS THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are ACLARIS THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-07 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Christopher Molineaux | 29,165,764 | -- | -- | 16,154,877 | 12,468,248 | Majority: yes |
| Elect Director: Vincent Milano | 42,267,754 | -- | -- | 3,052,887 | 12,468,248 | Majority: yes |
| Proposal 2: The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. The votes were cast as follows: | 29,025,583 | 16,273,816 | 21,242 | -- | 12,468,248 | Majority: yes |
| Proposal 3: The stockholders ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024. The votes were cast as follows: | 56,610,643 | 1,154,624 | 23,622 | -- | -- | Majority: yes |
Source: ACLARIS THERAPEUTICS INC., Form 8-K, filed with the SEC on 2024-06-07 — read the filing on EDGAR.
Each item below shows how the 106 asset managers that disclosed a ACLARIS THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
64% Majority: yes · of votes cast
ACLARIS THERAPEUTICS INC.’s own tally for this item (“Proposal 2: The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. The votes were cast as follows:”): 29,025,583 for, 16,273,816 against, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 71,264,786 outstanding shares: 41% for, 23% against (64% of the company cast a for/against vote).
The 106 asset managers below cast 50.6% of the shares they voted on this item FOR (16,652,025 for, 16,225,007 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,011,221 | 0 | 0 | 0 | For |
| BlackRock | 13,929 | 4,155,886 | 0 | 0 | Against |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | 0 | 0 | 0 | For |
| DE Shaw | 0 | 2,857,900 | 0 | 0 | Against |
| Fidelity | 1,292,803 | 1,488,450 | 0 | 0 | Against |
| Rock Springs Capital Management LP | 2,753,495 | 0 | 0 | 0 | For |
| Two Sigma | 0 | 1,726,873 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 1,565,250 | 0 | 0 | Against |
| State Street | 1,157,095 | 16,861 | 0 | 0 | For |
| Charles Schwab | 0 | 839,408 | 0 | 0 | Against |
| ACADIAN ASSET MANAGEMENT LLC | 0 | 700,735 | 0 | 0 | Against |
| Samsara BioCapital, LLC | 696,171 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 641,643 | 0 | 0 | 0 | For |
| Palo Alto Investors LP | 569,832 | 0 | 0 | 0 | For |
| Northern Trust | 541,822 | 3,742 | 0 | 0 | For |
| Citadel | 393,993 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 0 | 345,256 | 0 | 0 | Against |
| HighTower Advisors, LLC | 0 | 300,990 | 0 | 0 | Against |
| PNC BANK, NATIONAL ASSOCIATION | 0 | 270,000 | 0 | 0 | Against |
| STRS OHIO | 0 | 264,700 | 0 | 0 | Against |
| Aisling Capital Management LP | 196,513 | 0 | 0 | 0 | For |
| Equitable | 0 | 186,273 | 0 | 0 | Against |
| AQR | 0 | 182,931 | 0 | 0 | Against |
| BBR PARTNERS, LLC | 180,000 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 157,209 | 0 | 0 | Against |
Showing the 25 largest of 106 asset managers. See all 106 in the interactive database.
Combines 2 wordings of this item as funds reported it.
64% Majority: yes · of votes cast
ACLARIS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Christopher Molineaux”): 29,165,764 for, 16,154,877 withheld, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 71,264,786 outstanding shares: 41% for, 23% withheld (64% of the company cast a for/withheld vote).
The 34 asset managers below cast 100% of the shares they voted on this item FOR (7,104,668 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,882,172 | 0 | 0 | 0 | For |
| BlackRock | 0 | 0 | 2,706,426 | 0 | Abstain |
| Fidelity | 2,114,216 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 419,704 | 0 | Abstain |
| Equitable | 0 | 0 | 186,273 | 0 | Abstain |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 115,378 | 0 | Abstain |
| TIAA | 0 | 0 | 97,857 | 0 | Abstain |
| Lincoln Financial | 0 | 0 | 57,200 | 0 | Abstain |
| Pacific Life | 25,112 | 0 | 22,969 | 0 | For |
| T. Rowe Price | 47,442 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 34,229 | 0 | Abstain |
| Harbor ETF Trust | 30,304 | 0 | 0 | 0 | For |
| State Street | 0 | 0 | 24,620 | 0 | Abstain |
| Nationwide | 0 | 0 | 21,071 | 0 | Abstain |
| Blackstone Alternative Investment Funds | 0 | 0 | 16,300 | 0 | Abstain |
| Principal Exchange-Traded Funds | 0 | 0 | 16,142 | 0 | Abstain |
| ProShares | 0 | 0 | 15,939 | 0 | Abstain |
| SEI | 0 | 0 | 15,900 | 0 | Abstain |
| John Hancock | 0 | 0 | 14,788 | 0 | Abstain |
| Bridge Builder Trust | 0 | 0 | 12,653 | 0 | Abstain |
| DWS | 0 | 0 | 10,759 | 0 | Abstain |
| Jackson National | 0 | 0 | 8,881 | 0 | Abstain |
| Principal | 0 | 0 | 8,732 | 0 | Abstain |
| Calvert | 0 | 0 | 6,900 | 0 | Abstain |
| Guardian Variable Products Trust | 4,400 | 0 | 0 | 0 | For |
Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.
Combines 2 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
ACLARIS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Vincent Milano”): 42,267,754 for, 3,052,887 withheld, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 71,264,786 outstanding shares: 59% for, 4% withheld (64% of the company cast a for/withheld vote).
The 34 asset managers below cast 100% of the shares they voted on this item FOR (10,857,249 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,882,172 | 0 | 0 | 0 | For |
| BlackRock | 2,706,426 | 0 | 0 | 0 | For |
| Fidelity | 2,114,216 | 0 | 0 | 0 | For |
| Charles Schwab | 419,704 | 0 | 0 | 0 | For |
| Equitable | 125,873 | 0 | 60,400 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 115,378 | 0 | 0 | 0 | For |
| TIAA | 97,857 | 0 | 0 | 0 | For |
| Lincoln Financial | 57,200 | 0 | 0 | 0 | For |
| Pacific Life | 48,081 | 0 | 0 | 0 | For |
| T. Rowe Price | 47,442 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 34,229 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 30,304 | 0 | 0 | 0 | For |
| State Street | 24,620 | 0 | 0 | 0 | For |
| Nationwide | 21,071 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 16,300 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 16,142 | 0 | 0 | 0 | For |
| ProShares | 15,939 | 0 | 0 | 0 | For |
| SEI | 15,900 | 0 | 0 | 0 | For |
| John Hancock | 14,788 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 12,653 | 0 | 0 | 0 | For |
| DWS | 10,759 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 8,881 | 0 | Abstain |
| Principal | 8,732 | 0 | 0 | 0 | For |
| Calvert | 6,900 | 0 | 0 | 0 | For |
| Guardian Variable Products Trust | 4,400 | 0 | 0 | 0 | For |
Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.
Combines 2 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
ACLARIS THERAPEUTICS INC.’s own tally for this item (“Proposal 3: The stockholders ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024. The votes were cast as follows:”): 56,610,643 for, 1,154,624 against, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 71,264,786 outstanding shares: 79% for, 2% against (81% of the company cast a for/against vote).
The 34 asset managers below cast 100% of the shares they voted on this item FOR (10,928,560 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,882,172 | 0 | 0 | 0 | For |
| BlackRock | 2,706,426 | 0 | 0 | 0 | For |
| Fidelity | 2,114,216 | 0 | 0 | 0 | For |
| Charles Schwab | 419,704 | 0 | 0 | 0 | For |
| Equitable | 186,273 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 115,378 | 0 | 0 | 0 | For |
| TIAA | 97,857 | 0 | 0 | 0 | For |
| Lincoln Financial | 57,200 | 0 | 0 | 0 | For |
| Pacific Life | 48,081 | 0 | 0 | 0 | For |
| T. Rowe Price | 47,442 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 34,229 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 30,304 | 0 | 0 | 0 | For |
| State Street | 24,620 | 0 | 0 | 0 | For |
| Nationwide | 21,071 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 16,300 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 16,142 | 0 | 0 | 0 | For |
| ProShares | 15,939 | 0 | 0 | 0 | For |
| SEI | 15,900 | 0 | 0 | 0 | For |
| John Hancock | 14,788 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 12,653 | 0 | 0 | 0 | For |
| DWS | 10,759 | 0 | 0 | 0 | For |
| Jackson National | 8,881 | 0 | 0 | 0 | For |
| Principal | 8,732 | 0 | 0 | 0 | For |
| Calvert | 6,900 | 0 | 0 | 0 | For |
| Guardian Variable Products Trust | 4,400 | 0 | 0 | 0 | For |
Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.
Ranked by the number of ACLARIS THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 71,264,786 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 7.03% |
| 2 | BlackRock | 5.85% |
| 3 | Bain Capital Life Sciences Investors, LLC | 4.21% |
| 4 | DE Shaw | 4.01% |
| 5 | Fidelity | 3.90% |
| 6 | Rock Springs Capital Management LP | 3.86% |
| 7 | Two Sigma | 2.42% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 2.20% |
| 9 | State Street | 1.65% |
| 10 | Charles Schwab | 1.18% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. | 11.16% | 13G |
| Vanguard Group | 9.14% | 13F |
| BlackRock | 7.99% | 13F |
| Morgan Stanley | 5.72% | 13F |
| D.E. Shaw | 4.61% | 13F |
| Millennium Management | 4.59% | 13F |
| Renaissance Technologies | 2.35% | 13F |
| Geode Capital | 2.20% | 13F |
| State Street | 1.88% | 13F |
| Two Sigma | 1.87% | 13F |
Percentages above are of 71,264,786 shares outstanding, as reported by ACLARIS THERAPEUTICS INC. on its Form 10-Q dated 2024-04-30 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ACLARIS THERAPEUTICS INC.’s 10-Q dated 2024-04-30. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.
At ACLARIS THERAPEUTICS INC.'s shareholder meeting held 2024-06-06, in the 2023-2024 proxy season, 106 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 510 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our named executive officers, as… — FOR was 64% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ACLARIS THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-07.
ACLARIS THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2025-2026.